Key Highlights

  • PEPG shares rose 4.37% pre-market today to $5.49, after closing the prior session at $5.26.
  • PepGen priced 25,000,000 shares at $5.00 each, for expected gross proceeds of $125 million.
  • Underwriters hold a 30-day option to buy up to 3,750,000 additional shares at the offering price.
  • The 10 mg/kg Phase 2 cohort showed 46.5% mean splicing correction at Week 13.
  • Cash, cash equivalents and marketable securities were $104.8 million at September 30, before the offering.

PepGen (NASDAQ:PEPG) shares traded higher pre-market today after the company priced a $125 million public offering after the close on Wednesday. The stock was quoted at $5.49, up 4.37% from the prior close of $5.26. The $5.00 offering price sits about 4.9% below that close. The shares closed Wednesday up 14.10%, following the company's November 10 release of Phase 2 data and third quarter results.

PepGen is a Boston-based, clinical-stage biotechnology company founded in 2018. Its Enhanced Delivery Oligonucleotide technology uses cell-penetrating peptides to improve the uptake of conjugated oligonucleotide therapies. Its lead candidate, PGN-EDODM1, is being studied in myotonic dystrophy type 1 in the Phase 2 FREEDOM2-DM1 trial.

Offering Terms: 25 Million Shares at $5.00 With 3.75 Million More Available

All shares in the offering are being sold by PepGen. The underwriters have a 30-day option to buy up to 3,750,000 additional shares at the offering price, less discounts and commissions. The offering is expected to close on or about November 13, 2026, subject to customary closing conditions.

The company plans to use net proceeds to fund clinical development of its product candidate, plus Working Capital and general corporate purposes.

46.5% Splicing Correction at 10 mg/kg Frames the Raise

The company reported that the 10 mg/kg cohort showed mean splicing correction of 46.5% at Week 13, which it described as the highest reported in a multiple dose study. Five of six participants showed improvement above 20%, and four showed improvement above 50%. The company also reported gains in hand opening time, grip strength, a 10-meter walk/run test and the Timed Up and Go test.

PepGen reported no treatment discontinuations, serious or severe adverse events, or dose-limiting toxicities at that dose. A 12.5 mg/kg cohort is fully enrolled, with results expected in the first half of 2027.

The FDA issued a partial clinical hold on the FREEDOM2 study in March 2026, citing nonclinical findings in mice. The company said the study remains subject to the hold in the U.S. and that it is running additional mouse studies to answer FDA questions.

Third Quarter Loss of $19.4 Million Precedes the New Capital

PepGen reported a third quarter net loss of $19.4 million, or $0.28 per share, versus $18.0 million, or $0.52 per share, a year earlier. Research and Development expenses were $14.5 million, up from $13.4 million, and general and administrative expenses were $5.9 million, up from $5.2 million. Cash, cash equivalents and marketable securities totaled $104.8 million at September 30, which the company expects to fund operations into 2028 before the offering proceeds. The 52-week range is $1.31 to $7.80.

FDA Hold Response and 12.5 mg/kg Data Are the Next Items to Watch

PepGen enters the offering close with 10 mg/kg data in hand, a larger share count and a partial U.S. clinical hold still in place. The next items to watch are the closing of the offering around November 13, the company's response to FDA questions on the hold, and the 12.5 mg/kg results expected in the first half of 2027.